Bivin & Associates’s BioNTech BNTX Stock Holding History

Bivin & Associates’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$1K	–	353
2021 Q4	$1K	Buy	+3	New	+$822	﹤0.01%	282

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bivin & Associates's BNTX Position: Q1 2022 in Review

Bivin & Associates sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 3 shares — an estimated $1K sold.

Bivin & Associates first reported a position in BNTX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Bivin & Associates reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 3 BioNTech shares in Q1 2022, an estimated $1K.
Bivin & Associates first reported a position in BioNTech in Q4 2021 and held it in 1 quarter.
Bivin & Associates's BioNTech position peaked at $1K in Q4 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.